Prevalence of Hepatitis B Virus in Hemodialysis Patients Infected with Hepatitis C Virus in Mosul District / Iraq
AbstractMost problematic infection haemodialysis (HD) are at higher risk for acquiring Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections than the general population. Patients and Methods This study was carried out between January 2018 until July 2018, a total of (60) blood samples were collected from hemodialysis patients. The samples tested against anti-HCV, HBsAg anti-HBS and anti-HBC IgM, using ELISA technique and determination HBV-DNA, HCV-RNA viral load by Real time polymerase chain reaction. Results Prevalence HCV RNA was 12(20%) out of 60 patients were RT-PCR positive for HCV RNA with viral load, up to 100.000, Copy/ml and 10(16.69%) out of 60 patients were RT-PCR positive for HBV DNA in both positive and negative HCV RNA patients group with average viral load more than 100.000 copy/ml., 3 Patients out of 12 (25%) HCV RNA, positive patients were also positive for HBV DNA, while 40 (66%) out of 60 patients were anti-HBSAg positive, while the positivity of anti-HBCoIgM was 5 (50%). Conclusion The prevalence of co-infection hepatitis B and C was high in hemodialysis patients in Mosul district/Iraq
. H. Puttinge. A: Hepatitis B and C in peritoneal dialysis patients. Nephrol. 22:351,2017
. F. Fabrisi; G. Lunghi and P. Martin. Recent advances in the management of hepatitis C in dialysis population. Int. J. Artif. Organs. 25:503,2011.
. C. Brechot. D. Gozuacik. Y. Murakami et al: Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin cancer Biol. 10: 211, 2015.
. Y. Shiratiori; S. Shiina; P.Y. Zhang, et al: Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in j apan? Cancer. 80: 2060, 20017.
. C. Cauai; M.G. Pojula; I. Bastianoni, et al: Antibody testing and RT-PCR results in hepatitis C virus (HCV) infection HCV RNA detection in PBMC of plasma viremia-negative HCV seropositive persons. Infection 26: 151, 2008.
. W.E. Hitzler and S. Runkel. Routine HCV RNA screening of blood donations to identify early HCV infection in blood donors lacking antibodies to HCV. Transfusion 41:333, 2011.
. G. Mater; H. Sharara; G. Abdehnour, et al: Genotyping hepatitis C virus isolates from Lebanese hemodialysis patients by reverse transcription-PCR and restriction fragment length polymorphism analysis of 5 noncoding region. J. Clin. mocrobiol. 34:2623, 2006.
. Y.F. Liaw. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 22:1101-1108. 2005.
. A. Asberti; I. Pontisso; I. Fattovich; F. Bencegnu; S. Belussi and Demitri. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J. Hepatol. 22(suppl.1):38-41, 2005.
. H.N. Ohkawak; M. Yuki, and T. Kamada. Long term follow up hepatitis B virus and hepatitis C virus replicative levels in chronic hepatitis patients confected with bothe viruses. J. Med. Virol. 46:258-264, 2005.
. T. Allander; S. Medin; L. Jacovson; M. Persson. Hepatitis C transmission in an hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment. J. Med. Virol. 43: 415-419. 2004.
. S. Chiaramonte; M. Tagger; A. Ribero; M. Grossi, and G. Lagreca. Prevention of viral hepatitis in dialysis unit: isolatin and technical management of dialysis. Nephron 61:287-289. 2002.
. P. Druwe; A. Michielsen; M. Ramon and E. Debroe. Hepatitis C and nephrology. Nephrol. Dial. Transplant. 9:230-237. 2014.
. C. Pau; M. Cuervo; M. Ardila and Teran. Hepatitis C transmission through dialysis maehines. ASAIO (AM.SO.Artip. Itesn. Orgon) J. 40:M889M891. 2004.
. P. Dentico; R. Volpe; A. Buongiorno, and M. Manno. Hepatitis C virus in hemodialysis patients. Nephron 61: 307-308. 20017.
. C. Huang; S. Ho; S. Yang; L. Lee, and A. Tan. Hepatitis C marker in hemodialysis patients. J. Clin. Microbiol. 31: 1764-1769. 2003.
. Y. Irie; H. Hayashi. T. Yokozeki; T. Kashima and Okudak. Hepatitis C infection un related to blood transfusion in hemodialysis patients. J. Hepatol. 20: 557-559. 2016.
. G. Muller; A. Zabaleta; C. Arminio and N. Capriles. Risk factors for dialysis-associated hepatitis C in Venezuela. Kedney Int. 41:1055-1058. 2014.
. M. Sampietro; S. Badalamenti; N. Salvadori and C. Ponticelli. High prevalence of a rare hepatitis C virus in patients treated in same hemodialysis unit: evidence for nosocomial transmition of HCV. Kidney, Int. 46: 504-551. 2011.
. L. Stuyver; A. Claeys; W. vanArnhem; G. Maertens and M. Depaepe. Hepatitis C virus in hemodialysis unit: molecular evidence for nosocomial trans mission. Kidney Int. 49: 889-895. 2017.
. K. Okuda; S. Hoyashi; S. Kobaqoshi and Y. Irie. Mode of hepatitis C infection not associated with blood transfusion among chronic hemodialysis patients. J. Hepatol. 21: 28-31. 2009.
. R. Johnson; R. Wilson; W. Yamabe; M. Alpers and C. Wener. Renal manifestation of hepatitis C virus infection. Kidney Into 46: 1255-1263. 1994.
. V. Mioli; L. Balestra; P. Bibiano, and et al. Epidemiology of viral hepatitis in dialysis center: national survey. Nephron 61:278-283. 2002.
. R. Fukuda; N. Ishimura; M. Niigaki et al. Serological silent hepatitis B virus confection in patients with hepatitis C virus associated chronic liver disease: clinical and virological significance. J. Med. Virol; 58:201-7, 1999.
. Caccio; T. Policino; G. Squadrito; G. Cerenzia; M.E. Orlando; G. Raimondo. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl. J. Med.; 341:22-6, 2009.
. V. Goral; H. Ozkul; S. Tekes; D. Sit; A.K. Kadiroslu. Prevalence of occult HBV infection in hemodialysis patients with chronic HCV. World J. Gastroenterol; 12(21): 3420-4. 2006.
. M. Arababadi; G. Hassanshahi and H. Yousefi. HBV-DNA in Hemodialysis patients infected by HCV. Saudi J. Kidney Dis. Trans plant; 20(3): 398-401. 2009.
Copyright (c) 2020 American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who submit papers with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- By submitting the processing fee, it is understood that the author has agreed to our terms and conditions which may change from time to time without any notice.
- It should be clear for authors that the Editor In Chief is responsible for the final decision about the submitted papers; have the right to accept\reject any paper. The Editor In Chief will choose any option from the following to review the submitted papers:A. send the paper to two reviewers, if the results were negative by one reviewer and positive by the other one; then the editor may send the paper for third reviewer or he take immediately the final decision by accepting\rejecting the paper. The Editor In Chief will ask the selected reviewers to present the results within 7 working days, if they were unable to complete the review within the agreed period then the editor have the right to resend the papers for new reviewers using the same procedure. If the Editor In Chief was not able to find suitable reviewers for certain papers then he have the right to accept\reject the paper.B. sends the paper to a selected editorial board member(s). C. the Editor In Chief himself evaluates the paper.
- Author will take the responsibility what so ever if any copyright infringement or any other violation of any law is done by publishing the research work by the author
- Before publishing, author must check whether this journal is accepted by his employer, or any authority he intends to submit his research work. we will not be responsible in this matter.
- If at any time, due to any legal reason, if the journal stops accepting manuscripts or could not publish already accepted manuscripts, we will have the right to cancel all or any one of the manuscripts without any compensation or returning back any kind of processing cost.
- The cost covered in the publication fees is only for online publication of a single manuscript.